Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences Ruchika Sharma23 April 2025 10:30 AM ISTFoster City: Gilead Sciences, Inc. has announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that...
Merck injected version of Keytruda faces possible patent challenge: Report Ruchika Sharma6 March 2025 5:06 PM ISTMerck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute,...
Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell Carcinoma Ruchika Sharma27 Feb 2025 3:17 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Merck gets UK approval for lung disease drug Sotatercept Ruchika Sharma1 Jan 2025 3:13 PM ISTMerck has received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, to treat a rare lung...
Merck discontinues clinical development programs for vibostolimab, favezelimab Ruchika Sharma18 Dec 2024 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for...
Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck Ruchika Sharma11 Dec 2024 5:54 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA...
Merck's Injectable Keytruda Proves Effective in Trial, Promises Easier Cancer Treatment Farhat Nasim20 Nov 2024 2:01 PM ISTMerck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of lung cancer.
Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma Ruchika Sharma19 Nov 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer Ruchika Sharma3 Nov 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath-009, a pivotal...
Merck's KEYTRUDA Gains European Approval for Two New Gynecologic Cancer Treatments MD Bureau25 Oct 2024 5:47 PM ISTWith these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement.
MSD Phase 3 trial of head and neck cancer treatment meets primary endpoint Ruchika Sharma13 Oct 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA...
Anti cancer medicines now under Schedule H2 of Drugs Rules, Here is what it means Farhat Nasim12 Oct 2024 12:30 PM ISTNew Delhi: In order to track the movement of anti-cancer drugs and prevent counterfeiting, the Drug Technical Advisory Board (DTAB) has agreed to...
